解毒祛瘀滋阴方治疗系统性红斑狼疮:免疫重校准的系统级治疗策略
本综述系统检索1999年至2025年PubMed、Web of Science和CNKI中关于解毒祛瘀滋阴方(JP)治疗系统性红斑狼疮(SLE)的临床试验、临床前研究和多组学分析。临床证据显示含JP方案可降低SLEDAI评分、改善狼疮肾炎、减少糖皮质激素用量并提高生活质量;临床前研究揭示JP通过调节Th17/Treg平衡、抑制致病性B细胞、诱导双阴性T细胞凋亡、抑制IRAK1/NF-κB、激活FXR和Nrf2、逆转糖酵解重编程及重塑肠道菌群等多通路发挥系统治疗作用。
要点
- 含JP方案可降低SLE患者SLEDAI评分、改善狼疮肾炎并减少激素用量。
- JP通过恢复Th17/Treg平衡、抑制AKT/mTOR通路等调节免疫。
- JP可逆转淋巴细胞糖酵解重编程并重塑肠道菌群以维持免疫稳态。
核心结论
- JP作为靶向免疫失调、代谢重编程和肠道菌群失调的系统级治疗策略,支持「解毒祛瘀滋阴」中医原则与现代免疫学的整合。
研究设计与样本
- 纳入研究JP或其生物活性化合物在SLE中的临床与临床前证据。
主要发现
- 含JP方案显著降低SLE患者SLEDAI评分、减轻狼疮肾炎、减少糖皮质激素需求并改善生活质量。
- 在MRL/lpr狼疮倾向小鼠中,JP恢复Th17/Treg平衡,通过抑制AKT/mTOR抑制致病性B细胞增殖,并通过UBE2M介导的Bim上调促进双阴性T细胞凋亡。
- JP抑制巨噬细胞IRAK1/NF-κB信号,通过激活肾脏FXR抑制TGF-β1/α-SMA驱动的纤维化以减轻狼疮肾炎,并通过Nrf2激活减轻氧化损伤。
- JP通过AMPK信号逆转淋巴细胞病理性糖酵解重编程并恢复线粒体功能。
- JP重塑SLE模型肠道菌群,富集Akkermansia并调节短链脂肪酸和胆汁酸代谢以强化免疫稳态。
临床怎么用
- 对于SLE患者,可考虑在常规治疗基础上联用含JP方案以降低疾病活动度、改善狼疮肾炎并减少激素用量。
- JP的多靶点作用机制支持其作为SLE系统级治疗策略,尤其适用于存在免疫代谢紊乱和肠道菌群失调的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease involving immune dysregulation, metabolic reprogramming, and multi-organ damage. The Jieduquyuziyin prescription (JP), a contemporary Chinese herbal formula based on the Traditional Chinese Medicine principle of "Jiedu Quyu Ziyin," has shown clinical efficacy in SLE. This review aims to synthesize clinical and preclinical evidence explaining how JP achieves systemic therapeutic effects by targeting interconnected pathological pathways in SLE. METHODS: We systematically searched PubMed, Web of Science, and CNKI (January 1999-December 2025) for clinical trials, preclinical studies, and multi-omics analyses investigating JP or its bioactive compounds in SLE. RESULTS: Clinical evidence demonstrates that JP-containing regimens significantly reduce SLEDAI scores, alleviate lupus nephritis, lower glucocorticoid requirements, and improve quality of life in SLE patients. Preclinical studies in SLE-prone MRL/lpr mice reveal that JP targets key SLE pathogenic pathways: it restores Th17/Treg balance, suppresses SLE-associated pathogenic B cell proliferation via AKT/mTOR inhibition, and promotes apoptosis of double-negative T cells through UBE2M-mediated Bim upregulation. JP inhibits macrophage IRAK1/ NF-κB signaling, attenuates lupus nephritis by activating renal FXR to suppress TGF-β1/α-SMA-driven fibrosis, and mitigates oxidative damage via Nrf2 activation. Addressing SLE-associated immunometabolic dysfunction, JP reverses pathological glycolytic reprogramming in lymphocytes via AMPK signaling and restores mitochondrial function. Additionally, JP remodels gut microbiota in SLE models, enriching Akkermansia and modulating short-chain fatty acid and bile acid metabolism to reinforce immune homeostasis. CONCLUSION: This review validates JP as a system-level therapeutic strategy targeting immune dysregulation, metabolic reprogramming, and gut dysbiosis in SLE, supporting the TCM principle of "Jiedu Quyu Ziyin" and its integration with modern immunology.
引用
- Gan Y, Liu J, Zhou S, et al. Jieduquyuziyin prescription for systemic lupus erythematosus: a system-level therapeutic strategy for immunological recalibration. Chin Med. 2026. PMID: 41981676. doi:10.1186/s13020-026-01397-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。